Get started
Author

Marina Deodato

Observed names: Deodato, M, Deodato, Marina, M. Deodato
ORCID: 0000-0003-0010-6107
Observed ORCID: 0000-0003-0010-6107
OpenAlex ID: A5026430877
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study
2019 · Stefano Luminari, Michele Merli, et al. · Blood · 87
PDF
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
2023 · Anna Maria Frustaci, Marina Deodato, et al. · Cancers · 47
PDF
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial
2024 · Alessandra Tedeschi, Anna Maria Frustaci, et al. · The Lancet Oncology · 38
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study
2022 · Livio Pagano, Marianna Criscuolo, et al. · Blood Cancer Journal · 35
PDF
Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network
2019 · Marzia Varettoni, Emanuela Boveri, et al. · American Journal of Hematology · 33
PDF
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
2021 · Alessandra Tedeschi, Anna Maria Frustaci, et al. · Blood Advances · 30
PDF
Waldenstrom’s Macroglobulinemia: an Update
2017 · Maddalena Mazzucchelli, Anna Maria Frustaci, et al. · Mediterranean Journal of Hematology and Infectious Diseases · 27
PDF
Duvelisib for the treatment of chronic lymphocytic leukemia
2020 · Anna Maria Frustaci, Alessandra Tedeschi, et al. · Expert Opinion on Pharmacotherapy · 25
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia
2019 · Andrea Visentin, Marina Deodato, et al. · Hematological Oncology · 23
PDF
Duvelisib: A New Phosphoinositide-3-Kinase Inhibitor in Chronic Lymphocytic Leukemia
2019 · Anna M Frustaci, Alessandra Tedeschi, et al. · Future Oncology · 21
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study
2022 · Idanna Innocenti, Gianluigi Reda, et al. · Haematologica · 20
PDF
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment
2024 · Luca Arcaini, Côme Bommier, et al. · EClinicalMedicine · 16
PDF
Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.
2023 · Anna Maria Frustaci, Marco Montillo, et al. · Journal of Clinical Oncology · 13
PDF
Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells
2021 · Alessandra Trojani, Barbara Di Camillo, et al. · Cancers · 12
PDF
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies
2020 · Marzia Varettoni, Angela Ferrari, et al. · American Journal of Hematology · 12
PDF
Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL
2022 · Lydia Scarfò, Silvia Heltai, et al. · Blood · 10
PDF
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three‐factor model
2022 · Stefano Molica, Diana Giannarelli, et al. · American Journal of Hematology · 10
PDF
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes
2025 · Sara Pepe, Candida Vitale, et al. · Leukemia · 7
PDF
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study
2023 · Francesca R. Mauro, Irene Della Starza, et al. · Haematologica · 7
PDF
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia
2022 · Anna Maria Frustaci, Giovanni Del Poeta, et al. · Therapeutic Advances in Hematology · 7
Health‐related quality of life in Waldenstrom Macroglobulinemia and IgM‐related disorders: A single institution experience
2019 · Anna Maria Frustaci, Michele Nichelatti, et al. · Hematological Oncology · 7
A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients
2018 · Andrea Visentin, Marina Deodato, et al. · Blood · 7
Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing–Neel Syndrome
2025 · Anna Maria Frustaci, Arianna Zappaterra, et al. · American Journal of Hematology · 6
PDF
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia
2022 · Marina Deodato, Anna Maria Frustaci, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 6
Minimal Residual Disease-Driven Treatment Intensification By Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the Monotherapy and Combination Phases of the Improve Study
2020 · Lydia Scarfo, Silvia Heltai, et al. · Blood · 5
Works count: 95
Citation count: 580
H-index: 13
I10-index: 17
Year
Topic
Type